Incidence of acute endophthalmitis after intravitreal bevacizumab injection in a tertiary hospital

Aysun Taşdemir Arı; Mustafa Berhuni; Gizem Gürbostan Soysal; Nesime Setge Tıskaoğlu

Article Details

Incidence of acute endophthalmitis after intravitreal bevacizumab injection in a tertiary hospital

Authors:

Aysun Taşdemir Arı | Mustafa Berhuni | Gizem Gürbostan Soysal | Nesime Setge Tıskaoğlu

Publisher:

MediHealth Academy Yayıncılık

Main Topics:

Göz Hastalıkları

Journal:

Journal of Health Sciences and Medicine Vol.7 Issue 1, pp.13-16

Document Type:

Article

Publication Date:

1/2024

Document Language:

English

Document ID (Org No.):

2001309614

pISSN:

2636-8579

Keywords:

Abstract:

 Aims: To investigate the incidence of acute endophthalmitis after intravitreal bevacizumab injections. Methods: Patients who received treatment with intravitreal bevacizumab 1.25 mg0.05 ml injections for various indications between November 2020 and March 2022 were included in this retrospective study. The patients were followed up for 4 weeks after the injection in terms of acute endophthalmitis symptoms and signs. Results: Acute endophthalmitis developed in 1 patient after 4593 intravitreal bevacizumab injections were administered to 1427 eyes of 1026 patients, and the incidence was found to be 0.0217. The patient who developed acute endophthalmitis underwent pars plana vitrectomy and after 3 months, a significant improvement in visual acuity was observed. Conclusion: Development of endophthalmitis postoperatively was found to be moderately low after intravitreal bevacizumab injection. It was concluded that following asepsis rules and optimal bevacizumab preparation conditions could further reduce this.

 Aims: To investigate the incidence of acute endophthalmitis after intravitreal bevacizumab injections. Methods: Patients who received treatment with intravitreal bevacizumab 1.25 mg0.05 ml injections for various indications between November 2020 and March 2022 were included in this retrospective study. The patients were followed up for 4 weeks after the injection in terms of acute endophthalmitis symptoms and signs. Results: Acute endophthalmitis developed in 1 patient after 4593 intravitreal bevacizumab injections were administered to 1427 eyes of 1026 patients, and the incidence was found to be 0.0217. The patient who developed acute endophthalmitis underwent pars plana vitrectomy and after 3 months, a significant improvement in visual acuity was observed. Conclusion: Development of endophthalmitis postoperatively was found to be moderately low after intravitreal bevacizumab injection. It was concluded that following asepsis rules and optimal bevacizumab preparation conditions could further reduce this.

 Aims: To investigate the incidence of acute endophthalmitis after intravitreal bevacizumab injections. Methods: Patients who received treatment with intravitreal bevacizumab 1.25 mg0.05 ml injections for various indications between November 2020 and March 2022 were included in this retrospective study. The patients were followed up for 4 weeks after the injection in terms of acute endophthalmitis symptoms and signs. Results: Acute endophthalmitis developed in 1 patient after 4593 intravitreal bevacizumab injections were administered to 1427 eyes of 1026 patients, and the incidence was found to be 0.0217. The patient who developed acute endophthalmitis underwent pars plana vitrectomy and after 3 months, a significant improvement in visual acuity was observed. Conclusion: Development of endophthalmitis postoperatively was found to be moderately low after intravitreal bevacizumab injection. It was concluded that following asepsis rules and optimal bevacizumab preparation conditions could further reduce this.

 Aims: To investigate the incidence of acute endophthalmitis after intravitreal bevacizumab injections. Methods: Patients who received treatment with intravitreal bevacizumab 1.25 mg0.05 ml injections for various indications between November 2020 and March 2022 were included in this retrospective study. The patients were followed up for 4 weeks after the injection in terms of acute endophthalmitis symptoms and signs. Results: Acute endophthalmitis developed in 1 patient after 4593 intravitreal bevacizumab injections were administered to 1427 eyes of 1026 patients, and the incidence was found to be 0.0217. The patient who developed acute endophthalmitis underwent pars plana vitrectomy and after 3 months, a significant improvement in visual acuity was observed. Conclusion: Development of endophthalmitis postoperatively was found to be moderately low after intravitreal bevacizumab injection. It was concluded that following asepsis rules and optimal bevacizumab preparation conditions could further reduce this.

Article Details

Incidence of acute endophthalmitis after intravitreal bevacizumab injection in a tertiary hospital

Authors:

Aysun Taşdemir Arı | Mustafa Berhuni | Gizem Gürbostan Soysal | Nesime Setge Tıskaoğlu

Publisher:

MediHealth Academy Yayıncılık

Main Topics:

Göz Hastalıkları

Journal:

Journal of Health Sciences and Medicine Vol.7 Issue 1, pp.13-16

Document Type:

Article

Publication Date:

1/2024

Document Language:

English

Document ID (Org No.):

2001309614

pISSN:

2636-8579

Bevacizumab

Intravitreal injections

Endophthalmitis

Complications

Issues

Article Details

Incidence of acute endophthalmitis after intravitreal bevacizumab injection in a tertiary hospital

Authors: Aysun Taşdemir Arı | Mustafa Berhuni | Gizem Gürbostan Soysal | Nesime Setge Tıskaoğlu

Publisher: MediHealth Academy Yayıncılık

Main Topics: Göz Hastalıkları

Journal: Journal of Health Sciences and Medicine Vol.7 Issue 1, pp.13-16

Document Type: Article

Publication Date: 1/2024

Document Language: English

Document ID (Org No.): 2001309614

pISSN: 2636-8579

Bevacizumab

Intravitreal injections

Endophthalmitis

Complications

Issues

Authors:

Aysun Taşdemir Arı | Mustafa Berhuni | Gizem Gürbostan Soysal | Nesime Setge Tıskaoğlu

Publisher:

MediHealth Academy Yayıncılık

Main Topics:

Göz Hastalıkları

Journal:

Journal of Health Sciences and Medicine Vol.7 Issue 1, pp.13-16

Document Type:

Article

Publication Date:

1/2024

Document Language:

English

Document ID (Org No.):

2001309614

pISSN:

2636-8579